United States Opioids Market

The United States Opioids Market size is forecast to grow from approximately USD 24.84 Billion in 2025 to around USD 35.70 Billion by 2035. According to Decision Advisors, a detailed research report on the opioids market indicates that the Abuse-Deterrent trend dominates the market, accounting for approximately 15% of the total share in the United States. Purdue Pharma leads the market with an estimated 25-30% United States market share. The company's annual revenue of approximately USD 3.5-4 billion is making it one of the most influential forces shaping industry trends and overall market growth.

Market Snapshot

• United States Opioids Market Size (2025): USD 24.84Billion
• Projected United States Opioids Market Size (2035): USD 35.70Billion
• United States Opioids Market Compound Annual Growth Rate (CAGR): 3.69%
• Base Year: 2025
• Historical Period: 2021–2024
• Forecast Period: 2026–2035

Market Overview/Introduction

The United States opioids market refers to the production, distribution, and consumption of opioid-based medications used for pain management and treatment of opioid dependence within the US healthcare system. Opioids are a class of drugs that includes natural, semi-synthetic, and synthetic compounds, which bring relief to people who experience moderate to severe pain because these compounds interact with their opioid receptors. The market experiences growth because there is an increase in chronic pain cases, together with an older population and more people developing cancer who need palliative treatments. The development of abuse-deterrent formulations together with controlled drug delivery systems creates new possibilities for safer treatment methods. The future presents a prospect for non-addictive pain therapies, together with better monitoring technologies and significantly increased addiction treatments. Government initiatives and upcoming clinical guidelines will create an environment that supports sustainable market development in the upcoming years.

• The CDC implemented the Opioid Rapid Response Program to coordinate state and federal responses during opioid supply disruptions. It helped maintain patient access to treatment, reduced overdose risks, and strengthened communication between DEA, SAMHSA, and health agencies. The initiative improved continuity of controlled substance therapy and strengthened U.S. opioid crisis management.

•  The CDC developed a national overdose prevention strategy focusing on surveillance, harm reduction, and prescription monitoring. It supported naloxone distribution, improved prescribing guidelines, and enhanced real-time overdose tracking systems. The initiative helped reduce opioid-related deaths and guided public health responses during the ongoing U.S. opioid epidemic crisis.

Notable Insights: -

1. The semi-synthetic opioids segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period.
2. The oral segment dominated the market in 2025 and holds the largest market share, accounting for approximately 59.9% during the forecast period.
3. The hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 45% during the forecast period.
4. The compound annual growth rate of the United States Opioids Market is 3.69%.
5. The market is likely to achieve a valuation of USD 35.70Billion by 2035.

What is the role of technology in grooming the market?

Technology plays a crucial role in shaping the US opioids market by improving prescription monitoring, patient safety, and drug development. Advanced digital health systems, including electronic prescribing and real-time monitoring tools, help track opioid usage and reduce misuse or overprescribing. Integration of data analytics and AI enables healthcare providers to identify high-risk patients and personalize pain management strategies. Innovations in drug delivery systems, such as extended-release formulations and abuse-deterrent technologies, enhance treatment effectiveness while minimizing dependency risks. Additionally, telemedicine platforms have expanded patient access to pain management consultations, ensuring timely and controlled opioid prescriptions. Overall, technology supports a more regulated, efficient, and patient-centric approach, balancing the need for effective pain relief with efforts to reduce opioid-related harm in the US healthcare system.

Market Drivers

The US opioids market experiences its main growth driver through the rising elderly population, who require pain treatment because of their higher risk for chronic diseases, including arthritis and cardiovascular diseases, and cancer. A significant proportion of older adults experience persistent orthopedic and chronic pain, which leads to increased opioid usage. The annual rise in cancer cases generates ongoing requirements for strong and durable pain relief medications. The market expansion occurs because doctors now prescribe medications in new ways, which include continued morphine use and rising adoption of modern synthetic opioids. The US heroin market, which operates illegally, develops into an indirect force that shapes opioid distribution patterns and consumption practices.

Restrain

The US opioids market faces significant restraints due to stringent regulatory policies aimed at curbing misuse and addiction, alongside increasing awareness of opioid-related risks. Concerns over dependency, overdose, and side effects have led to cautious prescribing practices. Additionally, the growing preference for non-opioid and alternative pain management therapies further limits market growth.

Study on the Supply, Demand, Distribution, and Market Environment of the United States Opioids Market

The United States opioids market is shaped by a complex interplay of supply, demand, distribution, and regulatory environment. Demand is primarily driven by the high prevalence of chronic pain, post-surgical care, and cancer-related treatments, with opioids accounting for a significant share of pain management drugs in the country. On the supply side, the US relies heavily on a global pharmaceutical supply chain, where most raw materials and finished opioid drugs are sourced internationally, making availability sensitive to disruptions. Raw materials include opium poppy derivatives such as morphine and codeine, along with chemical precursors for synthetic opioids. Distribution occurs through regulated healthcare channels like hospitals and pharmacies, alongside illicit networks involving street markets and online platforms. Overall, strict regulations, global sourcing dependencies, and evolving distribution channels define the US opioids market environment.

Price Analysis and Consumer Behaviour Analysis

The price dynamics of the United States opioids market are influenced by strict regulatory controls, NHS pricing policies, and the availability of generic formulations, which keep prescription opioid prices relatively stable and affordable. However, branded and advanced formulations, such as extended-release or abuse-deterrent opioids, tend to be priced higher. From a consumer behavior perspective, there is increasing caution among patients and healthcare providers due to rising awareness of addiction risks and side effects. This has led to more conservative prescribing patterns and a gradual shift toward non-opioid alternatives where possible. Nevertheless, patients with severe or chronic pain, particularly cancer-related, continue to rely on opioids, ensuring consistent demand despite evolving perceptions and regulatory pressures.

Market Segmentation

The United States Opioids Market share is classified into drug type, application, route of administration, and end-user  

• The semi-synthetic opioids segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period.

Based on the drug type, the opioids market is divided into natural opioids, semi-synthetic opioids, and synthetic opioids. Among these, the semi-synthetic opioids segment dominated the market in 2025 and holds the largest market share, accounting for approximately 60% during the forecast period. The semi-synthetic opioids segment is driven by their balanced efficacy, safety, and versatility in pain management. Drugs such as oxycodone and tramadol are widely prescribed due to their controlled potency and availability in multiple formulations, including extended-release forms for chronic pain. Additionally, these opioids offer better pharmacokinetic control and adaptability compared to natural opioids, supporting their higher clinical preference.

• The oral segment dominated the market in 2025 and holds the largest market share, accounting for approximately 59.9% during the forecast period.

Based on the route of administration, the opioids market is divided into oral, injectable, transdermal, and others. Among these, the oral segment dominated the market in 2025 and holds the largest market share, accounting for approximately 59.9% during the forecast period. The oral segment in the U.K. is attributed to its convenience, cost-effectiveness, and high patient compliance. Oral formulations such as tablets and capsules are widely prescribed for chronic pain management, especially in outpatient settings. Additionally, ease of administration, availability of extended-release forms, and reduced need for clinical supervision further support their widespread adoption.

• The hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 45% during the forecast period.

Based on the end user, the opioids market is divided into hospitals, clinics, homecare settings, and rehabilitation centers. Among these, the hospitals segment dominated the market in 2025 and holds the largest market share, accounting for approximately 45% during the forecast period. The hospitals segment in the U.K. is driven by the high volume of surgical procedures, trauma cases, and inpatient care requiring strong pain management. Hospitals ensure controlled opioid administration under medical supervision, particularly for acute and post-operative pain, thereby increasing their overall consumption and market share.

Recent Development

• In September 2025, the International Narcotics Control Board (INCB) collaborated with the U.S. DEA under the GRIDS Programme to strengthen supply chain security of controlled substances. The initiative enhanced frontline enforcement capacity using intelligence-sharing tools to combat synthetic opioid trafficking and improved real-time monitoring of illicit drug networks in the United States.

• In July 2022, multiple U.S. states finalized settlement agreements with generic opioid manufacturers including Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan (Viatris), Sun, and Zydus, resolving allegations of their roles in the opioid crisis. The agreements provided multibillion-dollar funding for treatment, prevention, and recovery programs across the United States.

Competitive Analysis

The report offers the appropriate analysis of the key organisations/companies involved within the United States Opioids Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Top Key Companies in the United States Opioids market

• Purdue Pharma L.P.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Teva Pharmaceutical Industries Ltd.
• Mallinckrodt Pharmaceuticals
• Pfizer Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the United States, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the United States opioids market based on the below-mentioned segments

United States Opioids Market By Drug Type

• Natural Opioids
• Semi-Synthetic Opioids
• Synthetic Opioids

United States Opioids Market, By Route of Administration

• Oral
• Injectable
• Transdermal
• Others

United States Opioids Market, By End-User

• Hospital
• Clinics
• Homecare Settings
• Rehabilitation Centers

Frequently Asked Questions (FAQ)

Q. How has the opioid crisis changed prescribing behavior in the U.S.?

A. Healthcare providers have significantly reduced opioid prescriptions due to stricter guidelines and monitoring programs. Physicians now prioritize short-duration, lowest-effective-dose therapy and increasingly consider non-opioid alternatives for pain management.

Q. What role do Prescription Drug Monitoring Programs (PDMPs) play in opioid control?

A. PDMPs are state-level electronic databases that track controlled substance prescriptions. They help identify misuse, prevent doctor shopping, and support safer prescribing decisions, significantly reducing opioid diversion and overprescribing risks.

Q. How are pharmaceutical companies adapting to regulatory pressure in the opioid market?

A. Companies are shifting toward abuse-deterrent formulations, investing in non-opioid pain therapies, and diversifying pipelines into neurology and anti-addiction treatments to reduce dependence on traditional opioid revenues.

Q. What is the impact of the opioid market on healthcare system costs in the U.S.?

A. The opioid crisis has increased healthcare costs due to overdose treatments, addiction rehabilitation, emergency care, and productivity losses. This has led insurers and hospitals to implement stricter pain management protocols and preventive strategies.